Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.38 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10239258 | 0.93 | CYP3A4 (0.46) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL1390827 | 0.91 | ALDH1A1 (0.46) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL31260368 | 0.86 | CYP3A4 (0.51) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL31260302 | 0.86 | TSHR (0.45) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL31260295 | 0.84 | CYP3A4 (0.43) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL10239314 | 0.84 | TSHR (0.49) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL1391125 | 0.84 | ALDH1A1 (0.47) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL10239252 | 0.83 | TSHR (0.50) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL19259864 | 0.83 | TDP1 (0.46) | CYP3A4TSHRTDP1ATMALDH1A1 | |
| SCHEMBL1390971 | 0.82 | CYP3A4 (0.40) | CYP3A4TSHRTDP1ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207444-B | Bicyclic compounds | 武田药品工业株式会社 | 2020-07-24 | — | — | CN | disclosed |
| EP-3225618-B1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-10301292-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-28 | — | — | US | disclosed |
| US-20180002322-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3225618-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-10-04 | — | — | EP | disclosed |
| US-8501804-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| EP-2351743-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010247-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | CYP3A4 3464/4885TSHR 3927/4885TDP1 4400/4885 |
| US-20180002322-A1 | BICYCLIC COMPOUND | ACACA, ACACB, ACAT1 | CYP3A4 1320/4885TSHR 4716/4885TDP1 4465/4885 |
| US-10301292-B2 | Bicyclic compound | ACACA, ACACB, ACAT1 | CYP3A4 1320/4885TSHR 4716/4885TDP1 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.